Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20

1.

The timing of drug funding announcements relative to elections: a case study involving dementia medications.

Gill SS, Gupta N, Bell CM, Rochon PA, Austin PC, Laupacis A.

PLoS One. 2013;8(2):e56921. doi: 10.1371/journal.pone.0056921. Epub 2013 Feb 27.

2.

Drug policy: making effective drugs available without bankrupting the healthcare system.

Laupacis A, Anderson G, O'Brien B.

Healthc Pap. 2002;3(1):12-30. Review.

PMID:
12811107
3.

Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.

Molnar FJ, Man-Son-Hing M, Fergusson D.

J Am Geriatr Soc. 2009 Mar;57(3):536-46. doi: 10.1111/j.1532-5415.2008.02122.x. Epub 2009 Jan 29. Review.

PMID:
19187414
4.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
5.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

6.

International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH.

Pharmacoeconomics. 2010;28(10):813-30. doi: 10.2165/11536150-000000000-00000. Review.

PMID:
20831289
7.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
8.

External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Booth CM, Dranitsaris G, Gainford MC, Berry S, Fralick M, Fralick J, Sue J, Clemons M.

BMC Cancer. 2007 Jun 28;7:110. Review.

9.

Coverage with evidence development: the Ontario experience.

Levin L, Goeree R, Levine M, Krahn M, Easty T, Brown A, Henry D.

Int J Technol Assess Health Care. 2011 Apr;27(2):159-68. doi: 10.1017/S0266462311000018. Review.

PMID:
21473814
10.
11.

WITHDRAWN: Tacrine for Alzheimer's disease.

Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000202. Review.

PMID:
17636619
12.

Physostigmine for Alzheimer's disease.

Coelho F, Birks J.

Cochrane Database Syst Rev. 2001;(2):CD001499. Review.

PMID:
11405996
13.

Current implications for the managed care of dementia.

Stefanacci RG.

Am J Manag Care. 2007 Dec;13 Suppl 8:S203-5; discussion S206-7. Review.

14.

Cholinesterase inhibitors for Parkinson's disease dementia.

Maidment I, Fox C, Boustani M.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004747. Review.

PMID:
16437494
15.

Health technology funding decision-making processes around the world: the same, yet different.

Stafinski T, Menon D, Philippon DJ, McCabe C.

Pharmacoeconomics. 2011 Jun;29(6):475-95. doi: 10.2165/11586420-000000000-00000. Review.

PMID:
21568357
16.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
17.

Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.

Levy AR, Gagnon YM.

Healthc Pap. 2002;3(1):32-7; discussion 87-94. Review.

PMID:
12811108
18.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
19.
20.

Getting food policy on the Mayoral table: a comparison of two election cycles in New York and London.

Freudenberg N, Atkinson S.

Public Health. 2015 Apr;129(4):295-302. doi: 10.1016/j.puhe.2015.02.018. Epub 2015 Mar 30. Review.

PMID:
25834929
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk